Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies
Clinics in Liver Disease · 2026-05 · 30 (2) · xix-xx
DOI: 10.1016/j.cld.2026.02.001 ↗Kurz gefasst
Editorial in der Zeitschrift Clinics in Liver Disease, 2026-05. Verfasst von Zobair M Younossi. Beteiligte Einrichtung: The Global NASH/MASH Council (GNC), Center for Outcomes Research in Liver Diseases, Washington, DC, USA; The Global Center for Liver Outcomes & Polic….
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- The Global NASH/MASH Council (GNC), Center for Outcomes Research in Liver Diseases, Washington, DC, USA; The Global Center for Liver Outcomes & Policy Research, Georgetown University School of Medicine, Washington, DC,…
Zitieren
APA
Younossi, Z. M. (2026). Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies. Clinics in Liver Disease, 30(2), xix-xx. https://doi.org/10.1016/j.cld.2026.02.001
Vancouver
Younossi ZM. Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies. Clinics in Liver Disease. 2026;30(2):xix-xx. doi:10.1016/j.cld.2026.02.001
BibTeX
@article{Younossi2026,
author = {Younossi, Zobair M},
title = {Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies},
journal = {Clinics in Liver Disease},
year = {2026},
volume = {30},
number = {2},
pages = {xix--xx},
doi = {10.1016/j.cld.2026.02.001}
}
EUVIMED